ARCHIVES

Senate Investigates Opioid Manufacturers, Requests Study of Impact of DEA Policies

This article is from The Cancer Letter archive.

Vol. 38 No. 19 | May 11, 2012

Download PDF Visit The Full Archive

Related Articles

NCI’s Professional Judgment Budget Outlines Spending of $7.2 Billion

February 13, 2009

Clinical Trials: For ER+ Breast Cancer, Post-Tamoxifen, NSABP Testing Aromasin In Large Trial

June 1, 2001

HRSA: Discounts Owed on Some Orphan Drug Uses

October 24, 2014

New Jersey Legislature Votes to Oppose USPSTF PSA Screening Downgrade

January 20, 2012

NCI, DCT Board Cool Toward AMA, ACOS, VA Role In Clinical Trials

March 3, 1989

Interferon Results Cool Expectations, But Other Reports At ASCO/AACR Demonstrate Solid Progress

June 6, 1980